Attention Deficit Hyperactivity Treatment Disorder
Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years of age) as compared to adolescents. It is also known as hyperkinetic disorder / attention deficit disorder or neuropsychiatric disorder. The exact cause of the attention deficit hyperactivity disorder (ADHD) is not clear but expected to be due to genetic factors and environmental influences. The results indicate that the deficit hyperactivity / impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one’s task, unable to remember things, impatience, and being continuously in motion, among others.
The Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at a significant CAGR due to changing the quality of the births. Hyperactivity disorder among children about 4-17 year age group to be expected. Moreover, the patient’s attention is drawn to the increase in the care he has taken in the treatment of hyperactivity disorder. HOWEVER,
A sample of this report is available upon request @
The global attention deficit hyperactivity disorder treatment is segmented on the basis of medication type, age group, and distribution channel
Based on medication type, the attention deficit hyperactivity disorder has been segmented into following:
- stimulants
- amphetamines
- methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Non-Stimulants
- Atomoxetine
- Bupropion
- guanfacine
Based on the age group, the attention deficit hyperactivity disorder has been segmented into following:
- Pediatric
- Adolescent
- Adults
Based on the distribution channel, the attention deficit hyperactivity disorder has been segmented into following:
- Hospital pharmacies
- Specialty clinics
- Retail pharmacies
- Online pharmacies
To view TOC of this report is available upon request @
Nowadays, the global attention deficit hyperactivity disorder treatment market is in a nascent stage. Hyperactivity disorder treatment market share. For instance, in August 2011, MonoSol Rx, which again partnered with KemPharm to develop a second oral film product to treat attention deficit hyperactivity disorder treatment. Similarly, in May 2013, NeuroSigma received Health Canada approval for its monarch eTNS system for the treatment ofmajor depressive disorder and drug-resistant epilepsy, and attention deficit hyperactivity disorder. Approval for new products from various regulatory bodies such as U.S. Food and Drug Administration also fuel the growth of the attention deficit hyperactivity disorder treatment market. For instance, in September 2010, Actavis receives FDA approval of Atomoxetine HCl Capsules for the treatment of attention deficit hyperactivity disorder. Entering of generics into the market, and patent expiries are some key factors drive the attention deficit hyperactivity disorder treatment market growth over forecast period.
Globally, the attention deficit hyperactivity disorder has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest sharein global attention deficit hyperactivity disorder treatment market followed by Europe and Asia-Pacific. North America holds the largest share attributed to rising prevalence of attention deficit hyperactivity disorder, low threshold of diagnosis is expected to boost the of attention deficit hyperactivity disorder treatment therapeutics market in North America region over the forecast period. Moreover, increase in healthcare expenditure, ongoing clinical trials, early approval of drugs in the U.S., favourable insurance policies for brain monitoring technologies, and technological advancement for the treatment might fuel the attention deficit hyperactivity disorder treatment market. Europe accounts for the significant share attributed to increase in the population, rising prevalence of attention deficit hyperactivity disorder patients, and increased in research and development for the innovation of new products. Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder treatment market owing to developing healthcare infrastructure, government initiatives, a rise in population, and an increase in the number of mental disorders. Japan is the key region in attention deficit hyperactivity disorder treatment market owing to increase in the prevalence of attention deficit hyperactivity disorder among children which is approximately 7.7 %.
Need more information about this report @
Neos Therapeutics, Inc. (US), Pfizer Inc. (US), Supernus Pharmaceuticals, Inc. (US), Shire plc (Ireland), MonoSol Rx (US ), KemPharm, Inc. (US), Neurosigma, Inc. (US) and Actavis (US) to name a few.
Get access to full summary @